How useful is it clinically to analyse the K-ras mutational status for the diagnosis of exocrine pancreatic cancer? A systematic review and meta-analysis

European Journal of Clinical Investigation

Volumn 41, Issue 7, 2011, Pages 793-805

  Parker, Lucy A ^a,b   Lumbreras, Blanca ^a,b   Lopez, Tomás ^c   Hernández Aguado, Ildefonso ^a,b   Porta, Miquel ^b,c,d  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Diagnosis analysis; Diagnosis diagnostic use; Diagnosis methods; Epidemiology diagnosis; Genes; KRAS oncogene; Oncogene protein p21 ras; Pancreatic neoplasms diagnosis; Ras; Research methods

Indexed keywords

BIOLOGICAL MARKER; K RAS PROTEIN;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DISEASE MARKER; EXOCRINE PANCREATIC CANCER; EXTERNAL VALIDITY; FECES ANALYSIS; HUMAN; MEDLINE; META ANALYSIS; MUTATION; MUTATIONAL ANALYSIS; PANCREAS CANCER; PANCREAS JUICE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TISSUE SECTION;

GENES, RAS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 79955595503     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02495.x     Document Type: Review

References (63)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
2. Fernandez E, La Vecchia C, Porta M, Negri E, Lucchini F, Levi F. Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer 1994;57:786-92.
3. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72.
4. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 2005;7:189-97.
5. Michl P, Pauls S, Gress TM. Evidence based diagnosis and staging of pancreatic cancer. Clin Gastroenterol 2006;20:227-51.
6. Fry LC, Mönkemüller K, Malferthereiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 2008;393:883-90.
7. Porta M, Malats N, Piñol JL, Rifà J, Andreu M, Real FX. Diagnostic certainty and potential for misclassification in exocrine pancreatic cancer. J Clin Epidemiol 1994;47:1069-79.
8. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441-7.
9. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1998;53:549-54.
10. Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 1991;100:233-8.
11. Malats N, Porta M, Corominas JM, Piñol JL, Rifà J, Real FX. Ki-ras mutations in exocrine pancreatic cancer: associations with clinico-pathological characteristics and with tobacco and alcohol consumption. Int J Cancer 1997;70:661-7.
12. Okai T, Watanabe H, Yamaguchi Y, Mouri I, Motoo Y, Sawabu N. EUS and K-ras analysis of pure pancreatic juice collected via a duodenoscope after secretin stimulation for diagnosis of pancreatic mass lesion: a prospective study. Gastrointest Endosc 1999;50:797-803.
13. Trümper LH, Bürger B, von Bonin F, Hintze A, von Blohn G, Pfreundschuh M et al. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. Br J Cancer 1994;70:278-84.
14. Castells A, Puig P, Móra J, Boadas J, Boix L, Urgell E. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999;17:578-84.
15. Wenger FA, Zieren J, Peter FJ, Jacobi CA, Müller JM. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch Surg 1999;384:181-6.
16. Berger DH, Chang H, Wood M, Huang L, Heath CW, Lehman T et al. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer 1999;85:326-32.
17. Gress TM (ed). Molecular Pathogenesis of Pancreatic Cancer. Amsterdam: IOS Press, 2000.
18. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.
19. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-9.
20. Porta M (ed). A Dictionary of Epidemiology, 5th edn. New York: Oxford University Press, 2008. p. 66, 69, 191, 201, 227, 233-6, 255, 258.
21. Feinstein AR. Clinical Epidemiology. The Architecture of Clinical Research. Philadelphia: WB Saunders; 1985.
22. Fletcher RH, Fletcher SW. Clinical Epidemiology. The Essentials, 4th edn. Philadelphia: Lippincott, Williams & Wilkins; 2005.
23. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Clinical Epidemiology. How to Do Clinical Practice Research, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins; 2005.
24. Knotternuss JA, van Weel C, Muris JWM. Evidence base of clinical diagnosis: evaluation of diagnostic procedures. BMJ 2002;324:477-80.
25. Hernández-Aguado I, Porta M, Miralles M, García Benavides F, Bolúmar F. La cuantificación de la variabilidad en las observaciones clínicas. Med Clin (Barc) 1990;95:424-9.
26. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. Getting better but still not good enough. J Am Med Assoc 1995;274:645-51.
27. Porta M, Hernández-Aguado I, Lumbreras B, Crous-Bou M. 'Omics' research, monetization of intellectual property and fragmentation of knowledge: can clinical epidemiology strengthen integrative research? J Clin Epidemiol 2007;60:1220-5.
28. Lumbreras B, Parker LA, Porta M, Pollán M, Ioannidis JPA, Hernández-Aguado I. Overinterpretation of clinical applicability in molecular diagnostic research. Clin Chem 2009;55:786-94.
29. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 2002;12:1-6.
30. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189-202.
31. Sackett DL, Haynes RB. Evidence base of clinical diagnosis: the architecture of diagnostic research. BMJ 2002;324:539-41.
32. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
33. Lumbreras B, Porta M, Márquez S, Pollán M, Parker LA, Hernández-Aguado I. Sources of error and its control in studies on the diagnostic accuracy of '-omics' technologies. Proteomics Clin Applic 2009;3:173-84.
34. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 2005;51:1335-41.
35. Porta M, Ferrer-Armengou O, Pumarega J, López T, Crous-Bou M, Alguacil J et al. Exocrine pancreatic cancer clinical factors were related to timing of blood extraction and influenced serum concentrations of lipids. J Clin Epidemiol 2008;61:695-704.
36. Porta M, Malats N, Piñol JL, Real FX. Re.: diagnostic certainty in pancreatic cancer. Relevance of misclassification of disease status in epidemiologic studies of exocrine pancreatic cancer. Response to Silverman et al. J Clin Epidemiol 1996;49:602-3.
37. Porta M, Pumarega J, Ferrer-Armengou O, López T, Alguacil J, Malats N et al. Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study. Eur J Epidemiol 2007;22:577-88.
38. Soler M, Porta M, Malats N, Guarner L, Costafreda S, Gubern JM et al. Learning from case reports: diagnostic issues in an epidemiologic study of pancreatic cancer. J Clin Epidemiol 1998;51:1215-21.
39. Porta M, Costafreda S, Malats N, Guarner L, Soler M, Gubern JM et al. Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. Eur J Epidemiol 2000;16:533-41.
40. Ioannidis JP. Expectations, validity, and reality in omics. J Clin Epidemiol 2010;63:945-9.
41. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
42. Harbord RM (2008) Metandi: Stata Module for Meta-Analysis of Diagnostic Accuracy. Chestnut Hill, MA: Statistical Software Components, Boston College Department of Economics. Revised 15 Apr 2008.
43. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006;59:1331-2.
44. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90.
45. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 2009;6:e1000097.
46. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Inves 2010;40:35-53.
47. Urgell E, Puig P, Boadas J, Capellà G, Queraltó JM, Boluda R et al. Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer. Eur J Cancer 2000;36:2069-75.
48. Pellisé M, Castells A, Ginès A, Solé M, Mora J, Castellví-Bel S et al. Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fine-needle aspiration biopsy. Aliment Pharmacol Ther 2003;17:1299-307.
49. Villanueva A, Reyes G, Cuatrecasas M, Martínez A, Erill N, Lerma E et al. Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology 1996;110:1587-94.
50. Maire F, Micard S, Hammel P, Voitot H, Lévy P, Cugnenc PH et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 2002;87:551-4.
51. Porta M, Malats N, Guarner L, Carrato A, Rifà J, Salas A et al. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health 1999;53:702-9.
52. Parker LA, Porta M, Lumbreras B, López T, Guarner L, Hernández-Aguado I et al. Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. Eur J Epidemiol 2011; doi: (in press).
53. Porta M, Malats N, Corominas JM, Rifâ J, Piñol JL, Real FX et al. Generalising molecular results arising from incomplete biological samples: expected bias and unexpected findings. Ann Epidemiol 2002;12:7-14.
54. Porta M, Malats N, Vioque J, Carrato C, Soler M, Ruiz L et al. Incomplete overlapping of biological, clinical and environmental information in molecular epidemiologic studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health 2002;56:734-8.
55. Smidt N, Rutjes AW, van der Windt DA, Ostelo RW, Bossuyt PM, Reitsma JB et al. The quality of diagnostic accuracy studies since the STARD statement: has it improved? Neurology 2006;67:740-1.
56. Malumbres M, Barbacid M. RAS oncogenes: the first 30years. Nat Rev Cancer 2003;3:459-65.
57. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11.
58. Porta M, Ayude D, Alguacil J, Jariod M. Exploring environmental causes of altered ras effects: fragmentation + integration? Mol Carcinog 2003;36:45-52.
59. Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N et al. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res Rev 2009;682:83-93.
60. Maluf-Filho F, Kumar A, Gerhardt R, Kubrusly M, Sakai P, Hondo F et al. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol 2007;41:906-10.
61. Zheng M, Liu LX, Zhu AL, Qi SY, Jiang HC, Xiao ZY. K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses. World J Gastroenterol 2003;9:188-91.
62. Mora J, Puig P, Boadas J, Urgell E, Montserrat E, Lerma E et al. K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic masses: prospective study using two techniques with different detection limits. Clin Chem 1998;44:2243-8.
63. Van Laethem JL, Bourgeois V, Parma J, Delhaye M, Cochaux P, Velu T et al. Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest Endosc 1998;47:479-85.